Differential effect of a single high dose of the tricyclic antidepressant imipramine on interleukin-1β and tumor necrosis factor-α secretion following an in vivo lipopolysaccharide challenge in rats

International Journal of Immunopharmacology

Volumn 21, Issue 10, 1999, Pages 663-673

  Dredge, Keith ^a   Connor, Thomas J ^a   Kelly, John P ^a   Leonard, Brian E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Antidepressant; Corticosterone; Cytokine; IL 1 ; IL 10; Imipramine; Immunotoxicity; In vivo; LPS; TNF

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CORTICOSTERONE; IMIPRAMINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 1; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; IMMUNOCOMPETENCE; IMMUNOTOXICITY; MACROPHAGE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; SECRETION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CORTICOSTERONE; IMIPRAMINE; INTERLEUKIN-1; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MALE; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032842901     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(99)00042-9     Document Type: Article

References (37)

1. Andreis P.G., Neri G., Belloni A.S., Mazzocchi G., Kasprzark A., Nussdorfer G.G. Interleukin-1 β enhances corticosterone secretion by acting directly on the rat adrenal gland. Endocrinology. 129:1991;53-57.
2. Bateman A., Singh A., Kral T., Solomon S. The immune-hypothalamic-pituitary-adrenal axis. End. Rev. 10:1989;92-112.
3. Bencsics A., Elenkov I.J., Vizi E.S. Effect of morphine on lipopolysaccharide-induced tumor necrosis factor- α production in vivo: involvement of the sympathetic nervous system. J. Neuroimmunol. 73:1997;1-6.
4. Bering B., Moises H.W., Muller W.E. Muscarinic cholinergic receptors on intact human lymphocytes. Properties and subclass characterization. Biol. Psychiat. 12:1987;1451-1458.
5. Beutler B. TNF, immunity and inflammatory disease: lessons of the past decade. J. Invest. Med. 43:1995;227-235.
6. Bristow A.F., Mosley K., Poole S. Interleukin-1 β production in vivo and in vitro in rats and mice measured using specific immunoradiometric assays. J. Endocrinol. 7:1991;1-7.
7. Connor TJ, Harkin A, Kelly JP, Leonard BE. Olfactory bulbectomy provokes a suppression of interleukin-1 β and tumour necrosis factor- α production in response to an in vivo challenge with lipopolysaccharide: effect of chronic desipramine treatment. Neuroimmunomodulation 1999, in press.
8. Connor T.J., Dredge K., McNamara M., Kelly J.P., Leonard B.E. Immunomodulatory effects of 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy). Neuroimmunomodulation. 6:1999;211.
9. Costa P., Auger C.B., Traver D.J., Costa L.G. Identification of M3, M4, and M5 subtypes of muscarinic receptor mRNA in human blood mononuclear cells. J. Neuroimmunol. 60:1995;45-51.
10. Dayan A.D., Kuper F., Madsen C., Smialowicz R.J., Smith E., Van Loveren H., Vos J.G., White K.L. Report of validation study of assessment of direct immunotoxicity in the rat The ICICIS Group Investigators. Toxicology. 125:1998;183-201.
11. Dinarello C.A. Interleukin-1. Thomson A.W. The cytokine handbook. 2nd ed :1996;Academic Press, New York.
12. Dredge K., Kelly J.P., Leonard B.E. The effect of a single dose of imipramine on some immunotoxicological parameters in the rat. Med. Sci. Res. 26:1998;789-792.
13. Elenkov I.J., Hasko G., Kovacs K.J., Vizi E.S. Modulation of lipopolysaccharide-induced tumor necrosis factor- α production by selective α -and β -adrenergic drugs in mice. J. Neuroimmunology. 61:1995;123-131.
14. Fiorentino D.F., Zlotnik A., Vieira P., Mosmann T.R., Howard M., Moore K.W., O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146:1991;3444-3451.
15. Givalois L., Dornand J., Mekaouche M., Solier M.D., Bristow A.F., Ixart G., Siaud P., Assenmacher I., Barbanel G. Temporal cascade of plasma level surges in ACTH, corticosterone, and cytokines in endotoxin-challenged rats. Am. J. Physiol. 267:1994;R164-R170.
16. Gerard C., Bruyns C., Marchant A., Abramowicz D., Vandenabeele P., Delvaux A., Fiers W., Goldman M., Velu T. Interleukin-10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177:1993;547-550.
17. Grealy M., O'Donnell J.M. Secretion of growth hormone elicited by intravenous desipramine in the conscious, unrestrained rat. Br. J. Pharmacol. 102:1991;369-372.
18. Hamblin A.S. Cytokines. Dale M.M., Foreman J.C., Fan T.D. Textbook of immunopharmacology. 3rd ed :1994;Blackwell Scientific Publications, Oxford.
19. Hasko G., Szabo C., Nemeth Z.H., Kvetan V., Pastores S.M., Vizi E.S. Adenosine receptor agonists differentially regulate IL-10, TNF- α , and nitric oxide production in RAW 264.7 macrophages and endotoxemic mice. J. Immunol. 157:1996;4634-4640.
20. Hasko G., Szabo C., Nemeth Z.H., Lendvai B., Vizi E.S. Modulation by dantrolene of endotoxin-induced interleukin-10, tumour necrosis factor-α, and nitric oxide production in vivo and in vitro. Br. J. Pharmacol. 124:1998;1099-1106.
21. Hawes A.S., Rock C.S., Keogh C.V., Lowry S.F., Calvano S.E. In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin. Infect. Immunity. 60:1992;2641-2647.
22. Henderson B. Interleukin-1. Dale M.M., Foreman J.C., Fan T.D. Textbook of immunopharmacology. 3rd ed :1994;Blackwell Scientific Publications, Oxford.
23. Leonard B.E. Toxicity of antidepressants in overdose. Int. J. Clin. Pharm. Res. 9:(2):1989;101-110.
24. Leonard B.E. Pharmacology of antidepressants. Perspectives in Depression. 5:1997;1-5.
25. Mosmann T.R. Interleukin-10. Thomson A.W. The Cytokine Handbook. 2nd ed :1996;Academic Press, New York.
26. Muller T., Kuhn W., Kruger R., Przuntek H. Selegiline as immunostimulant: a novel mechanism of action. J. Neural Trans. 52:1998;321-328.
27. Pallardy M. Testing strategies in immunotoxicology. Toxicol. Lett. 95:(1):1998;12.
28. Rabkin J.G., Rabkin R., Harrison W., Wagner G. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am. J. Psychiat. 151:1994;516-523.
29. Rivier c., Chizzonite R., Vale W. In the mouse, the activation of the hypothalamic-pituitary-adrenal axis by a lipopolysaccaharide (endotoxin) is mediated through interleukin-1. Endocrinology. 125:1989;2800-2805.
30. Shen Y, Connor TJ, Nolan Y, Kelly JP, Leonard BE. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci 1999, in press.
31. Tracey K.J. Tumour necrosis factor-α Thomson A.W. The cytokine handbook. 2nd ed :1996;Academic Press, New York.
32. Van der Poll T., Jansen J., Endert E., Sauerwein H.P., Van Deventer S.J.H. Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interkeukin-6 production in human whole blood. Infect. Immun. 62:1994;2046-2050.
33. Vasilescu C., Berger D., Buttenschon K., Seidelmann M., Beger H.G. Endotoxin-induced release of interleukin-6 and interleukin-1β in human blood is independent of tumour necrosis factor-α Eur. Surg. Res. 28:1996;55-62.
34. Wong G.H.W., Goeddel D.V. Tumor necrosis factor-α and β inhibit virus replication and synergize with interferons. Nature. 323:1986;819-822.
35. Xia Z., DePierre J.W., Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 β and TNF- α release in human blood monocytes and IL-2 and interferon- γ in T cells. Immunopharmacology. 34:1996;27-37.
36. Xiao L., Eneroth P. Tricyclic antidepressants inhibit human natural killer cells. Toxicol. Appl. Pharmacol. 137:1996;157-162.
37. Zukerman S.H., Shellhaas J., Butler L.D. Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: effect of endogenous and exogenous glucocorticoids and the role of the pituitary adrenal axis. Eur. J. Immunol. 12:1989;301-305.